Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
16 hedge funds and large institutions have $1.52M invested in Aptose Biosciences, Inc. in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 4 closing their positions.
85% more capital invested
Capital invested by funds: $819K → $1.52M (+$699K)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 15 → 16 (+1)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$357K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$229K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$178K |
| 4 |
AA
Antipodean Advisors
New York
|
+$74.9K |
| 5 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$34.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$107K |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$95K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$60.2K |
| 4 |
Renaissance Technologies
New York
|
-$59K |
| 5 |
VF
Virtu Financial
New York
|
-$55K |
APTO Hedge Fund Activity: Q1 2018 in Review
16 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2018, worth a combined $1.52M — up 85% from $819K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new APTO positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $357K. The largest seller was Acadian Asset Management, cutting an estimated $107K.
- 16 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2018, up from 15 in Q4 2017.
- Funds reported $1.52M of Aptose Biosciences, Inc. stock for Q1 2018, up 85% quarter-over-quarter.
- 5 funds opened new Aptose Biosciences, Inc. positions in Q1 2018 and 4 closed out, a net change of +1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q1 2018 was Morgan Stanley, an estimated $357K added.
- The largest Aptose Biosciences, Inc. seller in Q1 2018 was Acadian Asset Management, an estimated $107K sold.
Based on aggregated 13F filings for Q1 2018.